Exscientia: Sanofi exercises Option on Exscientia-designed Bispecific Small Molecule for treatment of immunological conditions

Oxford, 5 August 2019: Exscientia, the world-leading Artificial Intelligence (AI)-driven drug discovery company, today announced that Sanofi has exercised its option to progress an innovative Bispecific Small molecule project it discovered as part of its new modality collaboration. The novel, first-in-class, bispecific investigational small molecule targets two distinct, biologically validated pathways related to inflammation and the progression of fibrosis. Commenting on this relationshi...